Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2014 Nov 3;111(45):15867–15868. doi: 10.1073/pnas.1418496111

Impact of early-stage HIV transmission on treatment as prevention

Kimberly A Powers a,1, Mirjam E Kretzschmar b,c, William C Miller a,d, Myron S Cohen a,d,e
PMCID: PMC4234559  PMID: 25368195

Timely HIV treatment improves health (1) and reduces transmission (2). These individual-level benefits of HIV treatment for both clinical and preventive purposes are well established, but several questions remain about the population-level impact of HIV treatment as prevention (3). In PNAS, Eaton and Hallett (4) use a mathematical model to address one such question: Does the proportion of transmission during early HIV infection affect the impact of HIV treatment on HIV incidence?

Transmission rates are sharply elevated during the first few months of HIV infection (5), likely due to increased viral concentrations (6) and founder virus transmission advantages that facilitate transmission at a lower inoculum (7). Quantifying the corresponding fraction of transmissions attributable to contact with persons in early-stage infection has been challenging, with mathematical modeling and phylogenetic studies producing a wide range of estimates (8, 9). Because HIV treatment typically begins well after the early period of heighted transmissibility, intuition tells us that the prevention benefit of HIV treatment programs will be compromised if a large fraction of transmission events are untouched. However, this prediction has been a matter of considerable debate (10).

Eaton and Hallett (4) approach this question with a mathematical model of HIV in South Africa. They used a Bayesian approach to calibrate their model to empirical HIV prevalence data, allowing for behavioral heterogeneity across individuals, changes in risk behavior over time, and varying levels of increased infectivity during early infection. They simulated treatment interventions against a range of scenarios consistent with the observed South African epidemic, allowing analysis of the relationship between early-stage transmission and treatment impact.

Surprisingly, the amount of unabated transmission from untreated people with early infection had little impact on long-term intervention effects. To explain these results, Eaton and Hallett refer to relationships among three quantities: the rate at which incident (new) cases increase at the outset of an epidemic (the initial growth rate), the basic reproductive number (R0), and the generation time (Tg). R0 is the average number of secondary infections that a typical infected person causes in a wholly susceptible population, and Tg is the average time between infection of an index case and his secondary cases.

If early HIV infection plays a large role in transmission (Fig. 1B), then the generation time distribution will be skewed toward smaller values (more rapid transmission on average). Thus, for a given, observed growth rate, R0 must be smaller. In contrast, if early HIV plays a smaller role (larger Tg), then R0 must be larger to achieve the same growth rate (Fig. 1A). Typically, the larger the R0, the more difficult an epidemic will be to control, because more effort is needed to reduce R0 below the value of 1 required for elimination (11).

Fig. 1.

Fig. 1.

Initial growth, generation time, and R0. Red circles represent new cases. The horizontal distance between one case and those directly connected to it represents generation time Tg. The number of arrows emanating from a case represents the basic reproductive number R0. Increases from one new case at time 0 to 16 new cases at time t is compatible with, for example, (A) two discrete generations after infection introduction, each with a longer time Tg between generations and R0 = 4; or (B) four discrete generations, each with a shorter Tg and R0 = 2. (In reality, generations will be distributed in time, but we present discrete generations to illustrate basic concepts.)

In the model of Eaton and Hallett, as the proportion of early-stage transmissions increased across scenarios, Tg decreased and R0 declined. That is, although the fraction of transmission events that are not prevented by treatment is greater in scenarios with large early-stage transmission contributions, R0 is lower. The lower R0 at the time of intervention initiation means that there are fewer secondary infections to prevent and the intervention is more likely to be effective. In other words, the increased role of early-stage transmission is detrimental to the intervention, but the lower R0 appears to perfectly counterbalance this effect.

Are we to take Eaton and Hallett’s model as the final word and assume that we need not worry about early HIV? We suggest that such a conclusion is premature for several reasons. First, the model predicts a moderate long-term impact of treatment: a 22% incidence reduction. That is, the intervention does not dramatically affect endemic prevalence. Near endemic prevalence, the system is relatively insensitive to changes in the reproductive number, because behavioral heterogeneity and saturation effects in high-risk groups buffer such changes. In other words, near-endemic incidence reductions are not expected to differ much across scenarios with different early-stage contributions and R0 values.

Second, the relationship between R0 and the effort required to control infection can be subtle for infections (like HIV) with a long infectious period and variable infectivity. In these situations, intervention performance depends not only on R0, but more importantly on the timing of transmission and intervention initiation within the infectious period (12). Increasing HIV testing rates to achieve earlier diagnosis can be expected to reduce the preintervention delay and improve the impact of treatment (Fig. 2). However, if most secondary infections occur early in infection, then effectiveness improvements will be limited as long as early-stage transmissions are unaffected. Therefore, in scaling up treatment to achieve more than a 22% incidence reduction, the role of early infection will be crucial (13).

Fig. 2.

Fig. 2.

Preintervention delay and intervention impact. Curves show the distribution of times within the infectious period that onward transmissions occur for two hypothetical scenarios that differ in terms of the early-stage transmission contribution. Red and green regions represent transmissions unaverted and averted by the intervention, respectively. The area under the curve represents R0. (A) Smaller proportion of early-stage transmissions (higher R0). (B) Higher proportion of early-stage transmissions (lower R0). In both scenarios, earlier intervention initiation (smaller T) will result in greater fractions of averted infections, but the prevention impact will be greater in A than in B as long as early transmission is missed.

Finally, variability in behavioral patterns across different epidemic settings is likely to be greater than the within-epidemic variability examined in South Africa, suggesting that the model may have limited applicability outside of a generalized, heterosexual epidemic. Indeed, phylogenetic analyses among men who have sex with men in Western settings, populations in whom treatment is widespread and incidence may be increasing (14, 15), suggest large early-stage contributions (16, 17).

HIV treatment coverage is increasing, causing decreased morbidity and mortality worldwide (18). HIV incidence appears to be decreasing in some (18) but not all (14, 15, 18) settings, indicating that HIV treatment as prevention is not yet achieving maximal gains. Eaton and Hallett use a well-founded argument to conclude that early-stage transmission may not compromise treatment as prevention in some settings. However, to take treatment as prevention forward toward an elimination goal, the role of early infection cannot yet be disregarded.

Acknowledgments

We thank Prof. Christophe Fraser for conceptualizing Fig. 1.

Footnotes

The authors declare no conflict of interest.

See companion article on page 16202.

References

  • 1.Thompson MA, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402. doi: 10.1001/jama.2012.7961. [DOI] [PubMed] [Google Scholar]
  • 2.Cohen MS, et al. HPTN 052 Study Team Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi: 10.1056/NEJMoa1105243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cohen MS, et al. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: Where do we go from here? Lancet. 2013;382(9903):1515–1524. doi: 10.1016/S0140-6736(13)61998-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Eaton JW, Hallett TB. Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence. Proc Natl Acad Sci USA. 2014;111:16202–16207. doi: 10.1073/pnas.1323007111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687–693. doi: 10.1086/590501. [DOI] [PubMed] [Google Scholar]
  • 6.Pilcher CD, et al. Amplified transmission of HIV-1: Comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS. 2007;21(13):1723–1730. doi: 10.1097/QAD.0b013e3281532c82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Carlson JM, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science. 2014;345(6193):1254031. doi: 10.1126/science.1254031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med. 2011;364(20):1943–1954. doi: 10.1056/NEJMra1011874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):277–282. doi: 10.1097/COH.0b013e32833a0d3a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Cohen MS, et al. HIV treatment as prevention: Debate and commentary—will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9(7):e1001232. doi: 10.1371/journal.pmed.1001232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press; Oxford: 1991. [Google Scholar]
  • 12.Bonačić Marinović AA, et al. Speed versus coverage trade off in targeted interventions during an outbreak. Epidemics. 2014;8:28–40. doi: 10.1016/j.epidem.2014.05.003. [DOI] [PubMed] [Google Scholar]
  • 13.Kretzschmar ME, Schim van der Loeff MF, Birrell PJ, De Angelis D, Coutinho RA. Prospects of elimination of HIV with test-and-treat strategy. Proc Natl Acad Sci USA. 2013;110(39):15538–15543. doi: 10.1073/pnas.1301801110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bezemer D, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS. 2008;22(9):1071–1077. doi: 10.1097/QAD.0b013e3282fd167c. [DOI] [PubMed] [Google Scholar]
  • 15.Birrell PJ, et al. HIV incidence in men who have sex with men in England and Wales 2001-10: A nationwide population study. Lancet Infect Dis. 2013;13(4):313–318. doi: 10.1016/S1473-3099(12)70341-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Brenner B, Wainberg MA, Roger M. Phylogenetic inferences on HIV-1 transmission: Implications for the design of prevention and treatment interventions. AIDS. 2013;27(7):1045–1057. doi: 10.1097/QAD.0b013e32835cffd9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Volz EM, et al. HIV-1 transmission during early infection in men who have sex with men: A phylodynamic analysis. PLoS Med. 2013;10(12):e1001568, discussion e1001568. doi: 10.1371/journal.pmed.1001568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Joint United Nations Programme on HIV/AIDS (2013) Global Report: UNAIDS report on the global AIDS epidemic 2013. Available at www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. Accessed October 2, 2014.

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES